BACKGROUND: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. METHODS: We investigated microglial activation with [(11)C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[beta-(11)C]dopa PET, acetylcholinesterase (AChE) activity with [(11)C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [(11)C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[beta-(11)C]dopa and [(11)C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. RESULTS: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. CONCLUSIONS: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality. Copyright 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. METHODS: We investigated microglial activation with [(11)C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[beta-(11)C]dopa PET, acetylcholinesterase (AChE) activity with [(11)C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [(11)C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[beta-(11)C]dopa and [(11)C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. RESULTS: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. CONCLUSIONS: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Andrew R Spector; Brittany N Dugger; Zbigniew K Wszolek; Ryan J Uitti; Paul Fredrickson; Joseph Kaplan; Bradley F Boeve; Dennis W Dickson; Audrey Strongosky; Siong-Chi Lin Journal: Ann Neurol Date: 2011-06 Impact factor: 10.422
Authors: Kacie D Deters; Shannon L Risacher; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Gary D Hutchins; Karmen K Yoder; Jill R Murrell; Salvatore Spina; Francine Epperson; Sujuan Gao; Andrew J Saykin; Bernardino Ghetti Journal: Am J Neurodegener Dis Date: 2014-12-05
Authors: J L Whitwell; K A Josephs; R Avula; N Tosakulwong; S D Weigand; M L Senjem; P Vemuri; D T Jones; J L Gunter; M Baker; Z K Wszolek; D S Knopman; R Rademakers; R C Petersen; B F Boeve; C R Jack Journal: Neurology Date: 2011-08-17 Impact factor: 9.910
Authors: Jonathan D Rohrer; Jennifer M Nicholas; David M Cash; John van Swieten; Elise Dopper; Lize Jiskoot; Rick van Minkelen; Serge A Rombouts; M Jorge Cardoso; Shona Clegg; Miklos Espak; Simon Mead; David L Thomas; Enrico De Vita; Mario Masellis; Sandra E Black; Morris Freedman; Ron Keren; Bradley J MacIntosh; Ekaterina Rogaeva; David Tang-Wai; Maria Carmela Tartaglia; Robert Laforce; Fabrizio Tagliavini; Pietro Tiraboschi; Veronica Redaelli; Sara Prioni; Marina Grisoli; Barbara Borroni; Alessandro Padovani; Daniela Galimberti; Elio Scarpini; Andrea Arighi; Giorgio Fumagalli; James B Rowe; Ian Coyle-Gilchrist; Caroline Graff; Marie Fallström; Vesna Jelic; Anne Kinhult Ståhlbom; Christin Andersson; Håkan Thonberg; Lena Lilius; Giovanni B Frisoni; Michela Pievani; Martina Bocchetta; Luisa Benussi; Roberta Ghidoni; Elizabeth Finger; Sandro Sorbi; Benedetta Nacmias; Gemma Lombardi; Cristina Polito; Jason D Warren; Sebastien Ourselin; Nick C Fox; Martin N Rossor; Giuliano Binetti Journal: Lancet Neurol Date: 2015-02-04 Impact factor: 44.182